NR1D1 and neoplasm: Consistent with increased levels of the prosurvival HSP90 molecules, REV-ERBα/β DKO cells exhibited relatively strong drug resistance compared with control cells (CTL) when treated with 17-AAG, a potent tumor-specific HSP90 inhibitor (Fig. 3G).